uniQure Prices Upsized $258.7M Public Offering at $45.50/Share, Underwriters Exercise Option in Full

summarizeSummary

uniQure N.V. priced an upsized public offering of ordinary shares, raising approximately $242.7 million in net proceeds at $45.50 per share, with underwriters fully exercising their option for additional shares.

check_boxKey Events

• Upsized Public Offering Priced

  uniQure priced an offering of 4,945,055 ordinary shares at $45.50 per share, totaling $225 million in gross proceeds for the firm shares. This finalizes terms of an offering initiated on 2026-06-22.

• Underwriters Fully Exercise Option

  Underwriters fully exercised their option on June 24, 2026, to purchase an additional 741,758 ordinary shares, bringing the total gross offering to approximately $258.7 million.

• Significant Capital Raise

  The company expects to receive approximately $242.7 million in net proceeds, providing substantial funding for its operations and commercialization plans.

• Moderate Discount

  The offering price of $45.50 per share represents a moderate discount of approximately 7.6% compared to the current stock price of $49.24.

auto_awesomeAnalysis

uniQure N.V. has finalized the pricing of its public offering, raising approximately $242.7 million in net proceeds. The offering was upsized from a previously announced $150 million to $225 million for firm shares, with an additional 741,758 shares purchased by underwriters through a fully exercised option, bringing the total gross offering to approximately $258.7 million. The shares were priced at $45.50, representing a moderate discount to the current market price. This substantial capital raise, representing nearly 8% of the company's market capitalization, provides critical funding for the company's operations and commercialization efforts, especially following recent regulatory developments for its Huntington's disease gene therapy, AMT-130.